Sugammadex Piramal Европейски съюз - български - EMA (European Medicines Agency)

sugammadex piramal

piramal critical care b.v. - sugammadex sodium - Невромускулна блокада - сугамадекс - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Talvey Европейски съюз - български - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - Множествена миелома - Антинеопластични средства - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Minjuvi Европейски съюз - български - EMA (European Medicines Agency)

minjuvi

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - Антинеопластични средства - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

CESTAL Cat 80/20 mg chewable tablets for cats България - български - БАБХ (Българска агенция по безопасност на храните)

cestal cat 80/20 mg chewable tablets for cats

levet pharmaceuticals ltd. - Празиквантел, Пирантела - таблетки за дъвчене - 20 mg/таблетка; 80 mg/таблетка - котки

Coxevac Европейски съюз - български - EMA (European Medicines Agency)

coxevac

ceva santé animale - инактивирана ваксина срещу coxiella burnetii, щам nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.